Medtronic's Hugo Robot Gains Ground: Time to Buy MDT?
💡 Key Takeaway
Medtronic's Hugo robot is gaining traction, and with strong financials, a growing dividend, and a cheap valuation, MDT stock looks attractive for long-term investors.
Medtronic's Hugo Robot Makes Strides
Medtronic (MDT) shares are down over 3% this year, but the company's Hugo robotic-assisted surgery (RAS) system is making significant progress. Just five years after its first procedure, Hugo is starting to challenge Intuitive Surgical's (ISRG) long-held dominance in soft-tissue robotics.
Medtronic received FDA approval for Hugo in urological procedures last December and submitted new regulatory filings in June to expand its use to general and gynecological surgeries. The company's first-quarter fiscal 2027 results were strong: revenue rose 13.7% year over year to $9.8 billion, and EPS jumped 40.7% to $1.14. Management raised full-year guidance for both revenue and earnings.
Hugo's modular design allows individual arms to be moved and shared across operating rooms, lowering costs for hospitals. It also integrates with Medtronic's Touch Surgery AI platform, powered by Nvidia infrastructure, creating recurring software and instrument revenue.
Medtronic is also approaching Dividend King status, having raised its dividend for 49 consecutive years. The stock trades at just 22 times trailing earnings and 15 times forward earnings, cheaper than most peers, with a 3.06% dividend yield.
Why This Matters for Investors
Medtronic's progress with Hugo is a direct threat to Intuitive Surgical's near-monopoly in robotic surgery. If Hugo continues to gain FDA approvals and adoption, it could capture a meaningful share of the $10 billion+ RAS market, driving years of growth for Medtronic.
The company's strong Q1 results and raised guidance show that its core businesses are performing well, even as it invests heavily in R&D and acquisitions. The planned spinoff of its diabetes business could unlock value and sharpen focus on higher-growth areas like robotics and cardiovascular.
For income investors, Medtronic's 49-year dividend growth streak and 3% yield offer a reliable income stream. The low valuation provides a margin of safety, especially compared to peers like Intuitive Surgical, which trades at a much higher multiple.
However, competition is fierce. Intuitive Surgical has a large installed base and deep relationships with hospitals. Medtronic will need to execute flawlessly to win share. Additionally, regulatory hurdles and hospital budgeting cycles could slow adoption.
Source: The Motley Fool
Analysis generated by Bobby AI quantitative model, reviewed and edited by our research team. This is not financial advice. Always do your own research before making investment decisions.
Bobby Insight
Buy MDT for its growing robotics franchise, reliable dividend, and discounted valuation.
Medtronic is successfully challenging Intuitive Surgical with its Hugo system, while its core businesses are growing double-digits. The stock's low valuation and 3% dividend yield provide a margin of safety and income, making it an attractive long-term investment.
What This Means for Me
